Get the Stockscreener App
10.45
1.06%
0.11
Pre-market:
10.89
0.44
+4.21%
Immix Biopharma Inc stock is traded at $10.45, with a volume of 1.32M.
It is up +1.06% in the last 24 hours and up +31.78% over the past month.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.
See More
Previous Close:
$10.34
Open:
$10.29
24h Volume:
1.32M
Relative Volume:
0.99
Market Cap:
$743.93M
Revenue:
-
Net Income/Loss:
$-34.98M
P/E Ratio:
-11.36
EPS:
-0.9199
Net Cash Flow:
$-32.77M
1W Performance:
-0.38%
1M Performance:
+31.78%
6M Performance:
+111.11%
1Y Performance:
+309.80%
1-Day Range:
$10.29
$11.12
1-Week Range:
$9.60
$11.12
52-Week Range:
$1.94
$11.61
Immix Biopharma Inc Stock (IMMX) Company Profile
Name
Immix Biopharma Inc
Sector
Industry
Phone
(888) 958-1084
Address
11400 WEST OLYMPIC BLVD., LOS ANGELES
Compare IMMX vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMMX
Immix Biopharma Inc
|
10.45 | 733.97M | 0 | -34.98M | -32.77M | -0.9199 |
VRTX
Vertex Pharmaceuticals Inc
|
529.59 | 126.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
649.81 | 65.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
916.80 | 57.70B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
313.04 | 40.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
189.99 | 39.82B | 742.00K | -1.37B | -1.07B | -7.0731 |
Immix Biopharma Inc Stock (IMMX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-25-26 | Initiated | Morgan Stanley | Overweight |
| Mar-09-26 | Initiated | Citizens | Mkt Outperform |
| Feb-09-26 | Initiated | Mizuho | Outperform |
Immix Biopharma Inc Stock (IMMX) Latest News
Immix Biopharma, Inc.(NasdaqCM: IMMX) added to Russell 2000 Index - marketscreener.com
Immix Biopharma, Inc.(NasdaqCM: IMMX) added to Russell 2500 Growth Benchmark - marketscreener.com
Immix Biopharma, Inc.(NasdaqCM: IMMX) added to Russell 2000 Growth Benchmark - marketscreener.com
Immix Biopharma, Inc.(NasdaqCM: IMMX) added to Russell 3000E Growth Benchmark - marketscreener.com
Immix Biopharma, Inc.(NasdaqCM: IMMX) added to Russell 3000 Growth Benchmark - marketscreener.com
Immix Biopharma, Inc. Actuals & Estimates (NASDAQ:IMMX) - TradingView
IMMX Forecast — Price Target — Prediction for 2027 - TradingView
Immix Biopharma Inc (IMMX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Immix Biopharma analyst bullish but flags safety, adoption questions - MSN
All you need to know about Immix Biopharma (IMMX) rating upgrade to buy - MSN
All You Need to Know About Immix Biopharma (IMMX) Rating Upgrade to Buy - Yahoo Finance
Immix Biopharma, Inc.(NasdaqCM: IMMX) added to S&P Biotechnology Select Industry Index - marketscreener.com
Wall Street analysts think Immix Biopharma (IMMX) could surge 113.58%: Read this before placing a bet - MSN
Immix Biopharma Analyst Bullish But Flags Safety, Adoption Questions - Benzinga
BofA initiates Immix Biopharma stock with buy rating on AL amyloidosis drug - Investing.com UK
Wall Street Analysts Think Immix Biopharma (IMMX) Could Surge 113.58%: Read This Before Placing a Bet - Yahoo Finance
Immix Biopharma, Inc. Stock 12‑Month Price Target Raised to $19.79, Implies 117% Upside - TradingView
IMMX Initiates Coverage by B of A Securities -- Rating Set to Bu - GuruFocus
This Talen Energy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Benzinga
BofA Securities Initiates Immix Biopharma(IMMX.US) With Buy Rating, Announces Target Price $27 - Moomoo
Immix Biopharma Inc (IMMX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Immix Biopharma Inc (IMMX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Immix Biopharma Inc (IMMX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
IMMX Initiates Coverage On LifeSci Capital -- Rating at Outperfo - GuruFocus
Immix Biopharma Inc (IMMX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Immix Biopharma Inc (IMMX) Institutional Confidence - TradingKey
Immix Biopharma Inc (IMMX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Immix Biopharma Inc (IMMX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Immix Biopharma Inc (IMMX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Immix Biopharma Initiated at Outperform by LifeSci Capital - Moomoo
IMMX Q1 2026 Earnings: EPS Beat Reflects Cost Discipline Amid Pre-Revenue Biotech Pipeline ProgressProfit Guidance Range - newsline.com
IMMX Q1 2026 Earnings: Biotech Reports Narrower-than-Expected Loss, Shares GainEPS Estimate Trend - newsline.com
Immix Biopharma Surges 5.3% as Biotech Sentiment Lifts IMMXProfit Surge Picks - newsline.com
Exploring 3 High Growth Tech Stocks in the US Market - simplywall.st
Wall Street analysts see a 120.59% upside in Immix Biopharma (IMMX): Can the stock really move this high? - MSN
What's going on with Immix Biopharma stock Thursday? - MSN
Janus Henderson files 13G/A: 9.09M shares of Immix Biopharma (IMMX) - Stock Titan
IMMX News | IMMIX BIOPHARMA INC (NASDAQ:IMMX) - ChartMill
These 10 small-cap U.S. healthcare companies carry the market's most expensive valuations - Seeking Alpha
IMMX Technical Analysis | Trend, Signals & Chart Patterns | IMMIX BIOPHARMA INC (NASDAQ:IMMX) - ChartMill
Immix Biopharma, Inc. Files Form 8-K Announcing Election of Directors and Corporate Details (May 2026) - Minichart
Immix Biopharma Shareholders Back Board and Auditor at AGM - TipRanks
Immix Biopharma (NASDAQ: IMMX) posts 2026 annual shareholder voting outcomes - Stock Titan
Immix Biopharma (IMMX) awards RSUs and stock options to director Helen Adams - Stock Titan
Immix Biopharma (IMMX) director Carey Ng awarded RSUs, 12,500-share option - Stock Titan
Immix Biopharma (NASDAQ: IMMX) grants RSUs and stock options to director - Stock Titan
Immix Biopharma (IMMX) CFO, President awarded 500,000 stock options at $8.78 - Stock Titan
Immix Biopharma (IMMX) director receives 6,250 RSUs and 12,500 options - Stock Titan
Immix Biopharma (IMMX) awards CEO 500,000 stock options at $8.78 strike - Stock Titan
Immix Biopharma (IMMX) director awarded RSUs and stock options in new grants - Stock Titan
Immix Biopharma (IMMX) board member receives new RSU and stock option awards - Stock Titan
Immix Biopharma Inc Stock (IMMX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Immix Biopharma Inc Stock (IMMX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Morris Gabriel S | CFO |
Dec 10 '25 |
Buy |
6.58 |
770 |
5,067 |
291,429 |
| Rachman Ilya M | CEO and Chairman |
Sep 17 '25 |
Buy |
2.02 |
2,500 |
5,050 |
1,140,937 |
| Morris Gabriel S | CFO |
Sep 16 '25 |
Buy |
1.97 |
2,600 |
5,122 |
290,659 |
0.05%
0.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):